The first drug shown to slow Alzheimer's disease progression has received full regulatory approval. The medication:
- Reduces cognitive decline by 27%
- Costs $26,000 per year
- Requires regular infusion
- Has significant side effects
Patient advocates celebrate the breakthrough while questioning access and affordability.
